ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

31604 results sorted by trial registration date.
  • Using the Internet to support breastfeeding duration

    The ‘Using the Internet to support breastfeeding duration’ project will be conducted from 2009-2013. Women from regional WA will be invited to take part in the project where they will be exposed to a high level of support through the Internet. The breastfeeding outcomes of these women will be compared with women from regional WA who only access those services normally available to them.

  • Evaluation of an internet-based treatment for comorbidity of alcohol disorders and depressive mood.

    The current study aims to evaluate the efficacy of an internet based psychological program for people who are concurrently depressed and drinking alcohol at harmful levels. This study is a randomised controlled trial with 3 comparison treatment, each with 200 participants who will be followed up for 12 months. The 3 treatments to be compared are: 1) brief intervention (BI) (1 module of motivation enhancement) 2) BI + self-guided modules (SG) (1 module of motivation enhancement + 5 modules of self-guided integrated treatment 3) BI + therapist-support (TS) (1 module of motivation enhancement + 5 modules of integrated treatment with email support from a therapist) Primary predictions are that 1) TS and SG interventions will have superior alcohol and depression outcomes at 3, 6, 9 and 12 months compared with BI and 2) TS will elicit greater client satisfaction and completion rate than SG, but SG will have similar treatment outcomes.

  • The research project is trying to find out if we can improve the results of best available chemotherapy for Chronic Lymphocytic Leukaemia (CLL) by the addition of a new drug called lenalidomide.

    to assess the effect of lenalidomide consolidation (vs observation with no further therapy) in previously untreated CLL patients with measurable disease after at least 4 cycles of FCR therapy.

  • Zinc and DNA Health

    Mild zinc deficiency has been reported in general aging populations due to numerous factors as previously reported by the International Zinc Nutrition Consultative Steering Committee. Zinc deficiency may cause impaired immunity, increased DNA damage, delayed wound healing, depression, impaired cognitive function and increased oxidative stress. As zinc deficiency can affect the health of ageing individuals, it is important to maintain an adequate zinc status within this population. To date, there is no data available on the benefits of zinc supplementation in an ageing Australian population.The findings of this research may provide knowledge on the effect of zinc supplementation in an elderly population in relation to DNA health (i.e. prevention of DNA damage). We believe there is a strong likelihood that these outcomes will be achieved by this study. Study hypotheses is zinc supplementation increases zinc status, reduces DNA damage and improves cell growth in both lymphocytes and buccal cells in elderly individuals.

  • Assessment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML)

    The target population for this study includes CML patients of any age residing in Australia or New Zealand with CML who have stopped TKI for any reason. Patients will be observed by there regular clinician and data submitted to the central trial coordinating centre.

  • The Clinical Characteristics of Children with Generalised Joint Hypermobility and thier Relationship to Adverse Outcomes

    Longitudinal Cohort study of outcomes in children with Joint hypermobility and the relationships between signs and symptoms, function, participation and outcomes.

  • The QUeensland Accelerated Risk Trial (QUART): Accelerated pathways in the assessment of suspected acute coronary syndrome in the Emergency Department.

    This study examines whether patients presenting to emergency with chest pain can be managed more rapidly than current standard care. The current process involves blood tests over 6-24 hours. The study study examines the safety of an ‘accelerated chest pain algorithm’ . That is whether combining the results of blood tests such as Troponin I, creatine-kinase MB fraction (CK-MB), and myoglobin over a 2 hour time period from presentation with a risk stratification process allows early futher testing or discharge of patients with potential acute coronary syndrome (ACS). These results will be used to develop a pathway for investigation of pateints with potential acute coronary syndrome (ACS) in the Emergency Department.

  • Changes in troponin for diagnosis of acute myocardial infarction (AMI) in an emergency department (ED) population with chest pain.

    The current process for diagnosing heart attack (acute myocardial infarction; AMI) is to take multiple blood tests to measure cardiac troponin. The current definition for AMI requires troponin levels to be elevated (greater than the 99th percentile of a reference population) and to display a rising or falling pattern. However, this definition remains controversial as there is no clearly defined, evidence based data for how much the troponin level should change. We aim to identify what change in troponin value (percentage increase in troponin) has the greatest diagnostic accuracy for diagnosis of AMI. We will focus on the change in combination with the 99th percentile decision limit, at 0-2 hours and 0-6 hours after presentation using the Beckman Coulter Access AccuTnI assay.

  • An evaluation of the benefits of frequent optimisation using QuickOpt in patients with Cardiac Resynchronisation Therapy Defibrillator Device (CRT-D)

    The purpose of this study is to prospectively evaluate the benefits of frequent AV/PV and V-V delay optimisation using QuickOpt in patients iwth CRT-D devices

  • The Impact of Weight Loss on the Metabolic Syndrome

    The rates of overweight and obesity are increasing in large numbers in many countries over the past 2 decades. Along with that, we are seeing increasing numbers of people with related health problems including high blood pressure, problems with cholesterol, and elevated blood sugar levels. These factors are a constellation which together are called the metabolic syndrome, and which give people a higher risk of developing diabetes and cardiovascular disease in the future. We wish to study people with metabolic syndrome to discover how these problems resolve with different degrees of weight loss. We also seek to understand better the relationship between gut hormones, obesity, inflammation within fatty tissue and the hormones and proteins fat cells secrete, and their effect on the factors of the metabolic syndrome.

Tags:
  • Finding clinical trials